# Tivicay (dolutegravir sodium) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dolutegravir

> The FDA approved Tivicay (dolutegravir sodium), sponsored by GSK plc (GSK), on June 12, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tivicay (dolutegravir sodium) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [HIV](https://sec-api.dev/indications/hiv) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### June 12, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213983 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200612, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY PD (DOLUTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213983%22

### June 12, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204790 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20200612, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY (DOLUTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204790%22

### July 9, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204790 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product TIVICAY (DOLUTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204790%22
- openFDA Drugs@FDA: "NDA213983 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product TIVICAY PD (DOLUTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213983%22

### April 15, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: HIV; HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05979311 (A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-15 (ACTUAL); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT05979311

### August 25, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA204790 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20260825, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY (DOLUTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204790%22
- openFDA Drugs@FDA: "NDA213983 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20260825, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY PD (DOLUTEGRAVIR SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213983%22

## Same indication

- [Alimatravir](https://sec-api.dev/pdufa/alimatravir) (MRK)
- [Cab ula](https://sec-api.dev/pdufa/cab-ula) (GSK)
- [Dtg/3tc](https://sec-api.dev/pdufa/dtg-3tc) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dolutegravir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tivicay (dolutegravir sodium) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dolutegravir

```bibtex
@misc{secapidev_pdufa_dolutegravir_20261116,
  title        = {Tivicay (dolutegravir sodium) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dolutegravir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dolutegravir_20261116","title":"Tivicay (dolutegravir sodium) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dolutegravir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
